AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA’s review of the drug back on track.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844